Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery

NCT00993798 is registered in ClinicalTrials.gov with Durect as lead sponsor.

NCT NCT00993798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00993798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
Lead sponsor
Durect
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
November 30, 2011
Enrollment
107 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

postoperative pain